Biorem Reports 2023 Financial Results including $0.14 earnings per share

In This Article:

GUELPH, ON, April 11, 2024 /CNW/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its results for the three and twelve-month periods ended December 31, 2023. Biorem's complete fiscal 2023 year-end financial statements and MD&A have been filed on SEDAR (www.sedar.com).

FINANCIAL HIGHLIGHTS:

In '000's except earnings per share



Thee-months ended

Twelve-months ended



December 31

December 31



2023

2022

2023

2022













Revenue

12,207

10,911

25,165

28,863

Gross profit

4,407

4,853

7,022

8,762

Operating Expenses

1,329

2,594

3,959

6,121

Ebitda*

3,270

1,342

3,441

2,775

Net earnings

2,364

789

2,179

1,613

EPS - basic

0.15

0.05

0.14

0.10

EPS - fully diluted

0.14

0.05

0.13

0.09

*Earnings before interest, taxes and amortization, a non IFRS financial measure

TWELVE MONTHS ENDED DECEMBER 31, 2023

For the twelve months ended December 31, 2023 revenue totaled $25.2 million compared to $28.9 million for the same twelve months in 2022. Net earnings for the year were $2.2 million compared to net earnings of $1.6 million in 2022. Earnings per share for the year increased by 40% to $0.14 per share against earnings per share of $0.10 basic and $0.09 fully diluted reported in 2022.

Gross profit for the year was $7.0 million, a 20% decrease from gross profit of $8.8 million recorded for the year-ended December 31, 2022.

Total operating expenses for the year were $4.0 million compared to $6.2 million of operating expenses in 2022. The $ 1.2 million decrease in operating expenses year over year was due to a decrease in commission expenses on the reduced revenues, the reversal of $373,000 in credit loss provisions that had been recorded in 2022 and one time legal and settlement expenses incurred in 2022 of approximately $700,000 related to the settlement of a long standing lawsuit.

On December 31, 2023 the Company had cash on hand of $2.3 million and working capital of $6.7 million compared to $3.8 million of cash and $4.9 million of working capital on December 31, 2022.  The decrease in cash on hand was largely due to the repayment of $775,000 of the Company's operating loan and the repayment of $525,000 of long term debt during the year.

Total order bookings for the year were $36.5 million, a 3% decrease in bookings over the record bookings in 2022 of $37.7 million. The Company's order backlog stood at $50.1 million on December 31, 2023 compared to $38 million on December 31, 2022.

"Management looks forward to beginning the next phase of the Corporation's development", said Derek S. Webb, President and CEO.  "A strong backlog; healthy bidding activity and a number of exciting new products introduced and under development promise to provide us with the tools necessary to achieve growth in 2024."